## 502532392 10/15/2013

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2

EPAS ID: PAT2577700

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

#### **CONVEYING PARTY DATA**

Name	Execution Date
ADRIAN HOBSON	04/23/2013

### RECEIVING PARTY DATA

Name:	ABBVIE INC.
Street Address:	1 NORTH WAUKEGAN ROAD
City:	NORTH CHICAGO
State/Country:	ILLINOIS
Postal Code:	60064

## PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	13808903

## CORRESPONDENCE DATA

Fax Number: (312)222-0818 Phone: (312) 222-0800

Email: chiipdocket@michaelbest.com

Correspondence will be sent via US Mail when the email attempt is unsuccessful.

Correspondent Name: LISA V. MUELLER

Address Line 1: 180 N. STETSON AVE., SUITE 2000

Address Line 4: CHICAGO, ILLINOIS 60601

ATTORNEY DOCKET NUMBER:	030270-1155-US00
NAME OF SUBMITTER:	LISA V. MUELLER
Signature:	/Lisa V. Mueller/
Date:	10/15/2013

Total Attachments: 2

 $source = P94073US\_SPW1007USO0\_ASGN-HobsonToAbbVieInc-10-15-13\#page1.tif\\ source = P94073US\_SPW1007USO0\_ASGN-HobsonToAbbVieInc-10-15-13\#page2.tif\\$ 

PATENT REEL: 031404 FRAME: 0748 OF \$40.00 13808903

# ASSIGNMENT

WHEREAS, Adrian Hobson, hereinafter called the "Assignor" has made the invention described in the United States patent application entitled "Spiro-Cyclic Amine Derivatives as S1P Modulators" that has a U.S. Patent Application Number of 13/808,903 filed on July 8, 2011.

WHEREAS, AbbVie Inc., a corporation, having a place of business at 1 North Waukegan Road, North Chicago, IL 60064, hereinafter called the "Assignee", desires to acquire the entire right, title and interest in and to the invention and to the patent application identified above, and all patents, foreign and domestic, which may be obtained for said invention, as set forth below.

NOW THEREFORE, in exchange for valuable and legally sufficient consideration, the Assignor has sold, assigned and transferred, and by these presents do sell, assign and transfer to the Assignee, the entire right, title and interest for the United States and elsewhere in and to the invention and the patent application identified above, and any patents that may issue for said invention in the United States and elsewhere; together with the entire right, title and interest in and to said invention and all patent applications, patents, utility models and designs therefore in all countries foreign to the United States, including the full right to claim for any such application all benefits and priority rights under any applicable convention; together with the entire right, title and interest in and to all continuations, divisions, renewals and extensions of any of the patent applications, patents, utility models and designs defined above; to have and to hold for sole and exclusive use and benefit of the Assignee, its successors and assigns, to the full end of the term or terms for all such patents.

The Assignor hereby covenant and agree, for both the Assignor and Assignor's legal representative, that Assignor has the full right to convey the interest assigned by this Assignment; and that the Assignor will assist the Assignee in the prosecution of the patent applications identified above, in the making and prosecution of any other applications that the Assignee may elect to make covering the invention identified above, in vesting in the Assignee like exclusive title in and to all such other patent applications and patents, in the prosecution of any interference which may arise involving said invention, or any such patent application or patent, and in assisting Assignee in enforcement of any rights arising out of the Assignment; and that the Assignors will execute and deliver to the Assignee any and all additional papers which may be requested by the Assignee to carry out the terms of this Agreement.

The Commissioner of Patents and Trademarks is hereby authorized and requested to issue patents to the Assignee in accordance with the terms of this Assignment.

IN TESTIMONY WHEREOF, the Assignor(s) has executed this agreement.

DATED: 4/23/13

Adrian Hobson